This study evaluated the efficacy and toxicity of the Hyper-CVAD regimen in treating adult acute lymphocytic leukemia (ALL). 204 adult patients with newly diagnosed ALL received alternating cycles of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and high-dose methotrexate and cytarabine, along with central nervous system prophylaxis and supportive care. Results showed that 91% of patients achieved complete remission and the 5-year survival and complete remission rates were 39% and 38% respectively, demonstrating superior outcomes compared to previous regimens. The Hyper-CVAD regimen was found to be an effective therapy for adult ALL that